Cetuximab
Monoclonal antibody
Evidence outlook
Approved: Head and Neck Squamous Cell Carcinoma, Metastatic Colorectal Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (5)
- BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) ERBITUX is indicated, in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy [see Dosage and Administration ( 2.3 )] .
- K-Ras Wild-type, EGFR-expressing Colorectal Cancer (CRC) ERBITUX is indicated for the treatment of K-Ras wild-type, epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer (mCRC) as determined by an FDA-approved test [see Dosage and Administration ( 2.2 )] : in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin) for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinoteca
- Treatment of EGFR-expressing, unresectable and advanced/recurrent colorectal carcinomas
- Colorectal Cancer ERBITUX (cetuximab) is indicated for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment. The benefits and risks of ERBITUX in combination with FOLFIRI, for first-line treatment in mCRC patients, have been observed only in a subgroup analysis of patients with ECOG performance status of 0 or 1 (see CLINICAL TRIALS). in combination with irinotecan in patients who are refractory to other irinotecan-based chemotherapy regimens. as a single...
- Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer: in combination with irinotecan-based chemotherapy; in first-line in combination with FOLFOX; as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan. For details, see section 5.1. Erbitux is indicated for the treatment of adult patients with BRAF V600E mutant metastatic colorectal cancer: in combination with encorafenib and FOLFOX for the first line treatment; in...
Development in Non-Small Cell Lung Cancer stopped (2012-09) for reasons the sponsor has not stated. Development continues in another indication. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00061815 NCT00061815 · Colorectal Cancer Registry: NCT00061815 | 3 | Compare overall survival in subjects with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-FU, and LV (FOLFOX4) and cetuximab with FOLFOX4 alone. (Every six weeks) 2004-12 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 3 more trials
NCT00154102 NCT00154102 · Metastatic Colorectal Cancer This was a large randomized, controlled trial, but it was open-label, so patients and doctors knew which treatment was given. Progression-free survival was assessed by an independent review committee; the all-patient comparison and the KRAS wild-type comparison favoured cetuximab, but the KRAS-mutant comparison, also registered as a primary endpoint, did not. Registry: NCT00154102 | 3 | Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments (Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006); Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments (Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006); Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments (Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006) 2006-12 | Progression-free survival (IRC), cetuximab + FOLFIRI vs FOLFIRI: median 8.9 vs 8.0 months, hazard ratio 0.853 (95% CI 0.728 to 1.000), p=0.0479 (n=599 each). Later KRAS analyses: wild-type HR 0.696 (95% CI 0.558 to 0.867), p=0.0012; mutant HR 1.171 (95% CI 0.887 to 1.544), p=0.2648 (CT.gov posted results). | Partial signal | link ↗ |
NCT02928224 NCT02928224 · Metastatic Colorectal Cancer Cetuximab was given in every arm, including the control arm, so this randomized trial tested the added BRAF and MEK inhibitors rather than cetuximab itself. The trial was also open-label, although its primary endpoints, overall survival and tumour response read by blinded central reviewers, are objective. Registry: NCT02928224 | 3 | (Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs) (Cycle 1 (up to 28 days)); (Safety Lead-in) Number of Participants With Adverse Events (AEs) (Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)); (Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Interim Analysis (Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)); (Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Final Analysis (From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)); (Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Interim Analysis (From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.1 weeks for triplet arm and 52.4 weeks for control arm)); (Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm (Duration of Phase 3, approximately 6 months (up to 28 days per cycle)) 2019-02-11 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT00079066 NCT00079066 · Colorectal Cancer This was a large randomized phase 3 trial with a control group, and its primary endpoint, overall survival, was significantly improved with cetuximab. Survival cannot be changed by knowing which treatment a patient received, but the trial was open-label, so it does not reach the strongest grade. Registry: NCT00079066 | 3 | Overall survival 2006-11-03 | Results not posted; external-source review pending | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (89)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (509)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (136)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (190)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (25)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (52)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (23)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Appears in other studies (20)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other EGFR drugs
Erlotinib, Gefitinib, Lazertinib, Osimertinib, Sunvozertinib and 36 more. Compare all 42 EGFR drugs
This mechanism is crowded: 41 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Head and Neck Squamous Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Cetuximab: this drug | Approved | Monoclonal antibody | EGFR | Partial signal | NCT00122460: Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Cetuximab Plus Chemotherapy 10.1 months (95% CI 8.6 to 11.2) | Chemotherapy Alone 7.4 months (95% CI 6.4 to 8.3) | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Erlotinib | Approved(overall) | Small molecule | EGFR | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Gefitinib | Approved(overall) | Small molecule | EGFR | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Lazertinib | Approved(overall) | Small molecule | EGFR | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02105636: Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05) | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Osimertinib (Tagrisso) | Approved(overall) | Small molecule | EGFR | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02358031: Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048). | |
| Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj) | Approved | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| Sunvozertinib (Zegfrovy) | Approved(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Almonertinib | Phase 3(overall) | Small molecule | EGFR | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Amivantamab | Phase 3 | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| Andamertinib | Phase 3(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Asandeutertinib | Phase 3(overall) | Small molecule | EGFR | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Becotatug | Phase 3(overall) | Monoclonal antibody | EGFR | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Befotertinib | Phase 3(overall) | Small molecule | EGFR | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| CPO301 | Phase 3 | Antibody–drug conjugate | EGFR | not yet graded | No reviewed efficacy summary in this indication | |
| FHND9041 | Phase 3(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Furmonertinib | Phase 3(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Icotinib | Phase 3(overall) | Small molecule | EGFR | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Limertinib | Phase 3(overall) | Small molecule | EGFR, EGFR T790M (resistant mutant, selective over wild-type EGFR) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| NBTXR3 | Phase 3 | Nanoparticle | Hafnium-oxide nanoparticle radioenhancer | not yet graded | No reviewed efficacy summary in this indication | |
| Pruvonertinib | Phase 3(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Rezivertinib | Phase 3(overall) | Small molecule | EGFR | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Rilertinib (SH-1028) | Phase 3(overall) | Small molecule | EGFR | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Volrustomig | Phase 3 | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Zipalertinib | Phase 3(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ordastobart | Phase 2/3 | Monoclonal antibody | OX40 (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Pimurutamab | Phase 2/3(overall) | Monoclonal antibody | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Zorifertinib | Phase 2/3(overall) | Small molecule | EGFR | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| BEBT-109 | Phase 2(overall) | Small molecule | EGFR | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Izalontamab | Phase 2 | Multispecific antibody | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| JS111 | Phase 2(overall) | Small molecule | EGFR | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Ozuriftamab Vedotin | Phase 2 | Antibody–drug conjugate | ROR2 | Partial signal | No reviewed efficacy summary in this indication | |
| Sutetinib | Phase 2(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ALE.P02 | Phase 1/2 | Antibody–drug conjugate | Claudin-1 (CLDN1) | not yet graded | No reviewed efficacy summary in this indication | |
| ANS02 | Phase 1/2(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| BBT-207 | Phase 1/2(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| BH-30643 | Phase 1/2(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| BPI-361175 | Phase 1/2(overall) | Small molecule | EGFR | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Dositinib Mesylate | Phase 1/2(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| DZD6008 | Phase 1/2(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| H002 | Phase 1/2(overall) | Small molecule | EGFR | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| JIN-A02 | Phase 1/2(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Pepinemab | Phase 1/2 | Monoclonal antibody | SEMA4D | not yet graded | No reviewed efficacy summary in this indication | |
| PH009-1 | Phase 1/2(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Silevertinib | Phase 1/2(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| STX-241 | Phase 1/2(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| VRN110755 | Phase 1/2(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ALX2004 | Phase 1(overall) | Antibody–drug conjugate | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| AST2303 | Phase 1(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| EPI-326 | Phase 1(overall) | Multispecific antibody | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| HLX42 | Phase 1(overall) | Antibody–drug conjugate | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| HSK40118 | Phase 1(overall) | Small molecule | EGFR | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Buparlisib | Discontinued | Small molecule | PI3K inhibitor (pan-class I) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(166 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Cetuximab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.